10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Archives : Old artciles

Sunday, November 15, 2009

Morepen Laboratories Ltd:Future growth prospects and outlook,buy/hold/sell,analysis and recomendation

Scripscan:Morepen Laboratories Ltd

Story:Morepen Laboratories Limited India manufacture APIs, Intermediates such as Loratadine, Desloratadine, Montelukast, Carvedilol, Pioglitazone, Fexofenadine and Atorvastatin and many more to export to more than 50 countries.Morepen has also integrated itself with manufacturing and marketing of finished dosage in a wide range of categories i.e. tablets, capsules and soft gels. Morepen has moved up its value chain by marketing for diagnostics and over the counter products (OTC) nationally as well as globally.Morepen also undertake contract development of Intermediates as per customer requirements.Over aggresive expansions and acquisitions killed this company some years ago.Its still struggling bigtime but future looks very uncertain to say the least.Its reeling with stiff competition and may well be an acuqisition candidate going forward.Shareholders may not have much to get as its already commanding a market cap of nearly 450crs.Retail investors with their huge fetish towards the penny priced stock fraternity would make sure that morepen always quote at par but to me this is more of a trading bet where one can look to have a position at 7-8rs only to exit at this 10-11 levels.If you are not a trader switch from this sick company to a better growth oriented candidate where capital appreciation as well as a good dividend yield backs you out.

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner